Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We expect to dispense with growing piles of paperwork, host a romper room for the official mascot and host a listening party with Mrs. Pharmalot (the rotation will feature this and this). And what about you? This is a fine time to gear up for spring cleaning or get a head start on planning a summer getaway. You could also plant yourself in front of the telly to binge watch. Or simply map out the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon…

A U.S. district court decision due as soon as Feb. 24 could have sweeping ramifications on access to abortion pills in the U.S., and reverse recent moves by the Biden administration to make it easier to get hold of them, Pharmaphorum says. Judge Matthew Kacsmaryk — who was appointed by Donald Trump — is due to rule in the weeks ahead on a lawsuit brought by anti-abortion group Alliance for Hippocratic Medicine that is seeking to force the U.S. Food and Drug Administration to rescind its decades-old approval of mifepristone. The outcome has sweeping implications for abortion medications and FDA authority over regulating drugs.


The Biden administration offered the first glimpse into how it is planning to enact a new law that will penalize drugmakers for hiking their prices faster than inflation, STAT writes. The initial guidance documents for drugs administered by physicians and sold in pharmacies offer details about the formulas that officials plan to use to calculate the penalties, and the process for fines if drugmakers do not comply. The guidance is open for public comment until March 11. Administration officials also confirmed that while the Inflation Reduction Act gives them authority to start charging drugmakers for penalties this year, they plan to delay sending invoices until 2025.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.